

# Biovance<sup>®</sup> Human Amniotic Membrane

Product Highlight


Biovance human amniotic membrane is an allograft intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Biovance membrane serves as a natural scaffold with an intact basement membrane, and has been found to support high levels of fibroblast and keratinocyte attachment.<sup>1</sup>

## Features and Benefits

- No preparation required
- Can be applied in any orientation
- Does not require sutures; 100 microns thick
- Room-temperature storage
- 10-year shelf life

## Primary Endpoint: Complications of Wound Dehiscence (%)

Study found a statistically significantly lower number of cases of incisional dehiscence with the use of Biovance membrane.<sup>2</sup>



Achieving early range of motion is important to a successful outcome and reduction of stiffness following total ankle replacement.<sup>2</sup>

**BIOVANCE<sup>®</sup>**  
Human Amniotic Membrane Allograft  
A Celularity Innovation

Biovance<sup>®</sup> is registered trademark of Celularity Inc.  
Biovance is manufactured for Arthrex by Celularity Inc., 170 Park Avenue, Florham Park, NJ 07932

**arthrex.com**

© 2021 Arthrex, Inc. All rights reserved. FL1-000478-en-US\_A

## Ordering Information

Product Description	Item Number
Biovance Amniotic Membrane, 1 cm × 2 cm	DHAM0012
Biovance Amniotic Membrane, 2 cm × 2 cm	DHAM0022
Biovance Amniotic Membrane, 2 cm × 3 cm	DHAM0023
Biovance Amniotic Membrane, 2 cm × 4 cm	DHAM0024
Biovance Amniotic Membrane, 3 cm × 3.5 cm	DHAM0035
Biovance Amniotic Membrane, 4 cm × 4 cm	DHAM0044
Biovance Amniotic Membrane, 5 cm × 5 cm	DHAM0055
Biovance Amniotic Membrane, 6 cm × 6 cm	DHAM0066

1. Bhatia M, Pereira M, Rana H, et al. The mechanism of cell interaction and response on decellularized human amniotic membrane: implications in wound healing. *Wounds*. 2007;19(8):207-217.
2. Brigido SA, Riniker ML, Protzman NM, Constant DD. Application of acellular amniotic scaffold following total ankle replacement: a retrospective comparison. *Clin Res Foot Ankle*. 6(3):275. doi:10.4172/2329-910X.1000275

The group treated with Biovance membrane began physical therapy **10 days earlier** than the control group<sup>2</sup>

To order, please call Arthrex at:  
**1-800-934-4404**

